

## TABLE OF CONTENTS

### **PLENARY SESSION**

Nathan B. Eddy Award Introduction .....	1-2
<i>M.W. Adler</i>	

Nathan B. Eddy Award Lecture.....	3-22
<i>M.J. Kreek</i>	

<b>SYMPOSIUM I.....</b>	23-25
Recent Advances on Inhalant Abuse	
<i>S.L. Cruz and R.L. Balster, Chairpersons</i>	

<b>SYMPOSIUM II</b>	
The Intersection of Drug Treatment and the Criminal Justice System.....	26-27
<i>M. Iguchi and H. Kleber, Chairpersons</i>	

<b>SYMPOSIUM VI</b>	
New Approaches to Non-Addictive Analgesics .....	28-31
<i>W.K. Schmidt and F. Porreca, Chairpersons</i>	

<b>SYMPOSIUM VII</b>	
Taking it to the Streets: Contingency Management for Real-Life Drug	
Abuse Treatment.....	32-35
<i>L. Amass and M.Y. Iguchi, Chairpersons</i>	

<b>SYMPOSIUM VIII</b>	
Pharmacology and Clinical Potential of Delta Opioid Agonists.....	36-40
<i>S. S. Negus and F. Porreca, Chairpersons</i>	

<b>SYMPOSIUM XI</b>	
A Stone Unturned: The Promise of GABAergic Modulation in	
Cocaine Dependence Treatment .....	41-43
<i>A.R. Childress and D.C.S. Roberts, Chairpersons</i>	

<b>SYMPOSIUM XII</b>	
Basic and Clinical Pharmacology of Selective Cannabinoid Receptor	
(CB1 and CB2) Antagonists.....	44-46
<i>S. Heishman and B.R. Martin, Chairpersons</i>	

<b>SYMPOSIUM XIII</b>	
Allelic Polymorphism of Human Opioid Receptors:	
Functional Studies.....	47-50
<i>K.S. LaForge and M.J. Kreek, Chairpersons</i>	

<b>SYMPOSIUM XIV</b>	
Developmental Follow-up of Prenatal Drug Exposure in Pre-School	
and School-Aged Children.....	51-53
<i>L.P. Finnegan and V.L. Smeriglio, Chairpersons</i>	

<b>SYMPOSIUM XV</b>	
Emerging Biological Targets for the Treatment of Nicotine Dependence.....	54-56
<i>R.S. Mansbach and L.P. Dwoskin, Chairpersons</i>	
<b>SYMPOSIUM XVI</b>	
From Caffeine to Opiates: Novel Interventions for Substance Use in Pregnancy .....	57-59
<i>D. Svikis and L. Finnegan, Chairpersons</i>	
 <b>ORAL COMMUNICATIONS I.....</b>	 60-63
Sex and the Single Drug	
 <b>ORAL COMMUNICATIONS II .....</b>	 63-66
The Brain in Pain	
 <b>ORAL COMMUNICATIONS III.....</b>	 67-70
Drug Abuse: The Next Generation	
 <b>ORAL COMMUNICATIONS IV .....</b>	 71-75
Form and Function	
 <b>ORAL COMMUNICATIONS V.....</b>	 75-79
There's no Substitute for Treatment	
 <b>ORAL COMMUNICATIONS VI.....</b>	 79-83
Drug Abuse in Adolescents	
 <b>ORAL COMMUNICATIONS VII .....</b>	 83-85
HIV and Hepatitis	
 <b>ORAL COMMUNICATIONS VIII.....</b>	 86-89
Where There's Smoke, There's Science	
 <b>ORAL COMMUNICATIONS IX.....</b>	 89-93
Strike up the Glands	
 <b>ORAL COMMUNICATIONS X.....</b>	 93-97
Role of Sex on Treatment Outcome	
 <b>ORAL COMMUNICATIONS XI.....</b>	 98-100
Risk Factors for Substance Abuse	
 <b>ORAL COMMUNICATIONS XII .....</b>	 101-105
Into the Brains of Primates	
 <b>ORAL COMMUNICATIONS XIII.....</b>	 106-110
The Downers Update	
 <b>ORAL COMMUNICATIONS XIV .....</b>	 110-112
Multifaces of Naltrexone	

<b>ORAL COMMUNICATIONS XV.....</b>	<b>112-116</b>
Agonist Treatment for Cocaine Dependence	
<b>ORAL COMMUNICATIONS XVI.....</b>	<b>116-117</b>
Cellular and Molecular Drug Effects	
<b>ORAL COMMUNICATIONS XVII.....</b>	<b>118-120</b>
Double Trouble	
<b>ORAL COMMUNICATIONS XVIII.....</b>	<b>121-124</b>
Pot Pourri	
<b>ORAL COMMUNICATIONS XIX.....</b>	<b>125-128</b>
Neurobiology	
<b>ORAL COMMUNICATIONS XX.....</b>	<b>128-132</b>
Stimulants: The Agonist and Ecstasy	
 <b>POSTER SESSION I.....</b>	 <b>133-185</b>
Personality and Disorders	
Impulsivity, Anger, Domestic Violence	
Vulnerable Populations and Drug Abuse	
Pharmacokinetics	
Methadone, LAAM, Buprenorphine	
Cocaine: Pharmacotherapy	
Cocaine/Opioid Interactions	
Opioids: Behavior	
Benzodiazepines and Inhalants	
 <b>POSTER SESSION II.....</b>	 <b>186-233</b>
Adolescents	
Nicotine and Caffeine	
Immune System	
Neuroendocrines and Stress	
Cocaine: Genetics, Neurophysiology	
Cocaine: Psychosocial Treatment	
Employment Issues	
Opioid Withdrawal	
Pain and Analgesia	
 <b>POSTER SESSION III .....</b>	 <b>234-279</b>
Amphetamines	
Imaging	
Cocaine: Cardiovascular Effects	
Opioid Receptors	
Cocaine: Dopamine and Serotonin	
Comorbidity	
Gender	
Women	
Epidemiology	

POSTER SESSION IV.....	281-329
Cannabinoids and THC	
NMDA/Sigma Receptors, Ibogaine	
Seizure and Locomotor Activity	
Perinatal Exposure and Development	
Pregnancy	
Methods and Assessment	
Opioids: Psychosocial Treatment	
HIV/AIDS	
LATE ABSTRACTS .....	330-331
ANNUAL REPORTS	
Biological Evaluation of Compounds for Their Physical Dependence Potential and Abuse Liability. XXIII. Drug Evaluation Committee of the College on Problems of Drug Dependence (1999).....	332-345
<i>A.E. Jacobson</i>	
Dependence Studies of New Compounds in the Rhesus Monkey, Rat, and Mouse (1999) .....	346-404
<i>M.D. Aceto, E.R. Bowman, L.S. Harris, and E.L. May</i>	
Evaluation of New Compounds for Opioid Activity (1999).....	405-422
<i>J.W. Woods, G.W. Winger, J.R. Traynor, M.-C. Ko, and F. Medzihradsky</i>	
Progress Report from the Testing Program for Stimulant and Depressant Drugs (1999) .....	423-433
<i>C.P. France, L.R. Gerak, J.W. Rowlett, W.L. Woolverton, G. Winger, and R.J. Briscoe</i>	
AUTHOR INDEX.....	434-448
SUBJECT INDEX.....	449-476